Zoetis Inc. has disclosed a recent transaction involving phantom stock units by its Chief Executive Officer, Kristin Peck. This filing, dated October 13, 2026, is significant as it underscores the company's strategy to align executive compensation with shareholder interests.
Founded in 2013, Zoetis Inc. is a leading provider of animal health products, focusing on the research, development, and manufacture of veterinary pharmaceuticals and vaccines. The company operates under the SIC code 2834, which corresponds to Pharmaceutical Preparations. It is publicly traded on the New York Stock Exchange under the ticker symbol ZTS.
The filing indicates that on October 9, 2026, Kristin Peck acquired 720.1441 phantom stock units, valued at $26.17 per unit. Following this transaction, she now holds a total of 66,915.04 shares. The phantom stock units are part of the Zoetis Supplemental Savings Plan, which allows for cash settlement following the executive's separation from service.
This transaction may impact various stakeholders, including shareholders who are interested in how executive compensation aligns with company performance. As Zoetis continues to innovate within the pharmaceutical preparations sector, such moves could influence perceptions of the company's governance and commitment to shareholder value.
Details were not available in the SEC filing regarding any future actions or implications from this transaction.